Experts from SmartStep Consulting regularly publish articles here on current, relevant topics from the healthcare, pharmaceutical and medical technology sectors. Here you can find an overview of all published blogposts.
This blog post provides a brief overview of the current discourse regarding the presentation of clinically relevant outcomes in the early benefit assessment.
This blog post addresses which factors influencing the reimbursement amount have been most significant in previous arbitration board decisions.
This blogpost addresses the relevance of a systematic literature search in the context of the AMNOG according to § 35a SGB V.
Our latest blog post looks at how the Arbitration Board makes decisions and also provides an overview of decisions made in 2022.
The quality of newly generated study data is a decisive factor after resubmission due to new scientific findings as well. Our latest blog post highlights the aspects of reassessment based on new scientific evidence according to chapter 5 section 13 of the German Social Code Book Five (SGB V).
This blogpost provides an overview of the re-evaluation of clinical trials in the context of the German AMNOG process and addresses the relevance of full HTA process support from a single source.
This blog post provides a brief overview of the status quo of DiGA fast track since the DVG went into effect in December 2019.
This article provides a brief overview of the key challenges facing European stakeholders, looks at the upcoming development steps of the project, and asks how manufacturers of medicines, medical devices, and other new health technologies can best prepare for an upcoming EU HTA process.
In this blogpost, SmartStep Consulting provides an overview and field report on “apps on prescription” – e-health as a future model in healthcare.